Philip Wagenheim Sells 36,800 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Philip Wagenheim sold 36,800 shares of the business’s stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $20.47, for a total transaction of $753,296.00. Following the transaction, the director directly owned 369,347 shares in the company, valued at $7,560,533.09. The trade was a 9.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Philip Wagenheim also recently made the following trade(s):

• On Monday, March 23rd, Philip Wagenheim sold 28,200 shares of Immunome stock. The shares were sold at an average price of $20.65, for a total transaction of $582,330.00.

Immunome Price Performance

Shares of NASDAQ IMNM traded up $0.74 during trading hours on Monday, hitting $20.75. 1,220,647 shares of the stock were exchanged, compared to its average volume of 1,315,932. Immunome, Inc. has a one year low of $5.15 and a one year high of $27.65. The company’s 50 day moving average is $22.76 and its 200 day moving average is $18.64. The firm has a market capitalization of $2.35 billion, a P/E ratio of -8.57 and a beta of 2.12.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Immunome had a negative return on equity of 57.61% and a negative net margin of 1,687.08%. Research analysts anticipate that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on IMNM shares. Guggenheim boosted their price objective on shares of Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. HC Wainwright initiated coverage on shares of Immunome in a research report on Thursday, February 12th. They issued a “buy” rating and a $40.00 price objective for the company. Lake Street Capital raised their price objective on Immunome from $22.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Finally, Truist Financial began coverage on Immunome in a report on Monday, December 1st. They set a “buy” rating and a $36.00 target price on the stock. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Immunome currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.45.

Hedge Funds Weigh In On Immunome

Institutional investors have recently bought and sold shares of the business. Stoneridge Investment Partners LLC raised its stake in Immunome by 5.4% in the 3rd quarter. Stoneridge Investment Partners LLC now owns 12,174 shares of the company’s stock worth $143,000 after purchasing an additional 620 shares in the last quarter. ANTIPODES PARTNERS Ltd grew its position in shares of Immunome by 6.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 10,892 shares of the company’s stock worth $128,000 after purchasing an additional 631 shares in the last quarter. Creative Planning increased its holdings in shares of Immunome by 4.0% during the third quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after purchasing an additional 710 shares during the period. Russell Investments Group Ltd. increased its holdings in shares of Immunome by 14.4% during the fourth quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock worth $159,000 after purchasing an additional 935 shares during the period. Finally, California State Teachers Retirement System raised its position in shares of Immunome by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock valued at $1,439,000 after buying an additional 1,167 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.